Safety and patient satisfaction of infliximab administration in an extramural setting supervised by a rheumatology specialist nurse.
- SourceAvailable from: intmed.unimaas.nl
Article: De vakgroep/afdeling Interne Geneeskunde herbergt drie medische specialismen: Interne Geneeskunde, Maag-darm-leverziekten en Reumatologie. Binnen het specialisme Interne Geneeskunde zijn 11 specialisaties aanwezig, namelijk algemeen interne geneeskunde; acute interne geneeskunde; consultatieve interne geneeskunde; endocrinologie; hematologie; infectieziekten; klinische immunologie; nefrologie; medische oncologie; ouderengeneeskunde; en vasculaire geneeskunde
- [Show abstract] [Hide abstract]
ABSTRACT: Objective To compare the clinical safety of the rapid infusion of infliximab (30-45 min) with the traditional one (2 h). Patients and method Open, prospective study with the consecutive inclusion of 150 patients with rheumatoid arthritis (RA) and/or spondyloarthritis (AS), resistant to conventional treatment. Patients were randomly distributed to receive 1.5 or 3 mg/kg (according to medical criteria) into 2 groups of 75 patients. Group A: patients received a rapid infusion of infliximab (30-45 min) and group B: traditional intravenous infusion (2 h). The rhythm of infusion was regulated through drip counts and the rule of threes and time was counted on a digital chronometer. Data was obtained from all patients included on possible side effects, as well as efficacy parameters (visual analog scale for pain, tender, and swollen joint counts), and comparisons were made between the rapid infusion group and the traditional infusion group. Results All patients concluded the study without serious complications. In the rapid infusion group 3 patients had hypersensitivity in the infusion arm and erythema was present in 7 more. The presence of side effects was not significantly different in relation with the infusion speed. Differences were not found in relation to the dosage or the type of illness (RA and/or AS) either. The efficacy of Infliximab for symptom control showed no differences using both types of infusion. Conclusions The absence of noticeable secondary effects associated with the reduction in the time of infusion of infliximab permits us to point out that a reduction in the time of infusion of infliximab can be a method to optimize hospital resources concerning the outpatient clinic for biologic therapy.Reumatología Clínica. 07/2007; 3(4).
- [Show abstract] [Hide abstract]
ABSTRACT: Tocilizumab is an effective therapy for patients with moderate to severe rheumatoid arthritis that is administered by infusion over one hour every 4 weeks. The community-based infusion (ACTiv) program was introduced to Australia in August 2010 to provide accessible and convenient treatment for patients with rheumatoid arthritis who require tocilizumab. The primary objectives of this study were to determine the characteristics of patients in the ACTiv program, patient satisfaction, and patient-perceived benefits and concerns with the ACTiv program, and drivers of patient satisfaction and patient-perceived benefits and concerns. A voluntary self-administered survey was given to all 608 patients in the ACTiv program between January 27, 2011 and March 31, 2011. A total of 351 surveys were returned completed, giving a response rate of 58% (351/608). Most patients in the ACTiv program were women aged 40-64 years, with a mean disease duration of 13.7 years and moderate disability, who had been in the ACTiv program for ≥5 months. Most patients (88%, 302/342) were either very satisfied or satisfied with the ACTiv program and believed that they were very unlikely or somewhat unlikely to switch from the ACTiv program (64%, 214/335). The most important benefit was the reassurance of receiving treatment from a trained nurse in a professional medical environment (33%, 102/309). The most important concern was the fear of side effects (48%, 134/280). The main drivers of patient satisfaction and patient-perceived benefits and concerns of patients were health profile, previous medication experience, and length of treatment time in the program. The ACTiv program is used by patients of various ages, family life situations, and locations. Patient satisfaction with the program is high, which enables patients to benefit from long-term use of tocilizumab.Patient Preference and Adherence 01/2012; 6:275-83. · 1.49 Impact Factor
2006 65: 276Ann Rheum Dis
Y van Eijk, A Boonen, G Schulpen, et al.
supervised by a rheumatology specialist nurse
administration in an extramural setting
Safety and patient satisfaction of infliximab
Updated information and services can be found at:
Article cited in:
This article cites 2 articles, 1 of which can be accessed free at:
the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in the box at
To order reprints of this article go to:
go to: Annals of the Rheumatic DiseasesTo subscribe to
group.bmj.com on July 23, 2010 - Published by ard.bmj.comDownloaded from
Safety and patient satisfaction of infliximab administration
in an extramural setting supervised by a rheumatology
Y van Eijk, A Boonen, G Schulpen, V Schrijnemaekers, H Fiolet, Sj van der Linden
Ann Rheum Dis 2006;65:276. doi: 10.1136/ard.2005.036566
insufficient capacity at their hospital’s day care centre to
administer the drug. Therefore, we explored the possibility of
administering infliximab in an extramural setting supervised
by a rheumatology specialist nurse (RSN).
A vacant room in a nursing home 5 km from the hospital
was prepared as the infusion facility. Two nurses and the
nursing home physician were given details of the clinical
aspects of RA, with emphasis on treatment with infliximab.
The hospital infliximab protocol, including the screening
before each infusion, the preparation and administration of
infliximab, and the safety procedure, was adapted. A form to
guarantee communication between the hospital and the
extramural setting was developed. Arrangements with the
hospital pharmacy were made to assure punctual delivery of
the exact number of infliximab vials to the extramural setting
on the day of the infusion. The infusions were organised and
supervised by the RSN once a week.
At the start of the project, all patients with RA attending
the day care centre for infliximab infusions completed a
questionnaire and an interview was carried out. Information
was obtained on demographic and disease characteristics,
previous problems related to the infusion treatment, the EQ-
Satisfaction with treatment was measured on a visual
analogue scale (0–100; higher values better satisfaction)
and by a self composed questionnaire comprising 33 items
(four point Likert scale) over seven domains covering
information, accessibility, professionalism, courtesy of per-
sonnel, recreation possibilities, accommodation, and conti-
nuity of care. At the new infusion centre, all administrative
and clinical events connected with the administration of
infliximab were recorded prospectively. After 6 months, the
patients again completed the EQ-5D and satisfaction ques-
After a pilot with eight patients, all 57 remaining patients
with RA who had received at least four infusions in the
hospital completed the screening questionnaire in September
and October 2002. Forty (70%) patients were female, with a
mean (SD) age of 54 (14.8) years, mean disease duration 12.3
(10.3) years, mean duration of infliximab administration
13.1 (6.8) months. Four patients were not considered eligible
by the rheumatologist owing to events during one of the
previous infusions or comorbidity, 13 refused extramural
treatment for personal reasons, and nine had stopped the
infusions before continuing extramurally because of the
inefficacy of infliximab. Overall, the patients not participat-
ing were older (56 (17.3)) than the other patients (51 (12.7)).
Of those who refused to change to the extramural setting, the
schedule of a weekday infusion was unsuitable (54%) or they
were resistant to change for non-obvious reasons (46%).
Those with personal reasons for resistance were older (58
fter introduction of reimbursement of the cost of
infliximab for the treatment of patients with active
rheumatoid arthritis (RA),1
several hospitals had
(18.5)) than those who had a practical reason (45 (14.9)). No
differences in comorbidity were found between these two
In September 2004, 24 of the initial 31 patients were still
receiving infusions. All other patients stopped the infusion
because of lack of efficacy. After telephone consultation with
the rheumatology nurse, a planned infusion was postponed
on 10 occasions because the patient had a minor infection. A
total of 341 infusions were carried out, and the nursing home
physician was contacted 24 times. Twice the infusion was
postponed, twice an allergic skin reaction was treated with H1
antagonists and three times the infusion speed was reduced
because of uncomplicated illness. Twenty three patients
completed the 6 months’ evaluation.
Patients reported increased satisfaction with information
provided about the treatment and its safety, and the
increased possibility for contact with peers. Global satisfac-
tion with infliximab administration improved from 74 (SD
12) to 81 (21) (paired t test: p=0.05) and the EQ-5D from
0.44 (0.33) to 0.60 (0.25) (paired t test: p=0.09).
Administration of infliximab organised and supervised by
an RSN in an extramural setting is feasible and safe. Older
patients participating in the project reported improved
satisfaction, especially with information on several aspects
of the treatment. This shows that intramural treatment can
be improved by giving more and better information about
treatment. Although treatment by an RSN was initially begun
because the hospital had insufficient capacity, fewer patients
than expected started intravenous infliximab infusions,
because subcutaneous products became available. However,
the success of treatment in an extramural setting will be
generalised to administration of infliximab for other condi-
tions and other intravenous drugs.
Y van Eijk, G Schulpen, V Schrijnemaekers, H Fiolet, Department of
Integrated Care, University Hospital, Maastricht, The Netherlands
A Boonen, Sj van der Linden, Department of Internal Medicine, Division
of Rheumatology, Caphri Research Institute, University Hospital
Maastricht, The Netherlands
Correspondence to: Ms Y van Eijk, Department of Integrated Care,
University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The
Accepted 18 June 2005
1 Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR,
et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis.
Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant
Therapy Study Group. N Engl J Med 2000;343:1594–602.
2 EuroQol Group. EuroQol - a new facility for the measurement of health-
related quality of life. Health Policy 1990;16:199–208.
group.bmj.com on July 23, 2010 - Published by ard.bmj.comDownloaded from